Camil Mireștean Călin Gheorghe Buzea Irina Butuc Alexandru Zara Dragoș Teodor Iancu

Abstract

Xerostomia is commonly associated with the radio-chemotherapy treatment of the head and neck cancers. The risk increases with increasing doses received by the parotid. Severe xerostomia (defined as long-term salivary function of < 25% of baseline) may be avoided if at least one parotid gland receives less than 20 Gy. The combined treatment with cisplatin regarded as bringing a significant benefit in survival with concurrent radiotherapy is associated with increased risk of late toxicity. Intensity-modulated radiotherapy (IMRT) is considered the radio-therapeutic standard in the management of head and neck cancer. Purpose: to evaluate the possibility of modern techniques to reduce radiation doses to parotid glands compared to conventional 3D-CRT radiotherapy even if the parotid glands are not delineated as organs at risk (OAR) and dosimetric constraints are not applied. Methods: For 10 locally advanced nasopharyngeal cancer cases treated by radiotherapy with curative intent using 3D-CRT technique, alternative IMRT and VMAT plans were proposed without applying dosimetric constraints for parotid glands. Results: IMRT and VMAT techniques reduce the maximum dose (Dmax) and the mean dose (Dmean) for both parotid glands compared to the 3D-CRT technique. The treatment plans were comparatively analyzed in terms of doses received by both parotid glands. Conclusions: Modern radiotherapy techniques implementation can reduce the dose received by the parotids even in the absence of contouring them as organs at risk, reducing xerostomia and ensuring a better quality of life for the nasopharynx cancer radio-treated patients.

##plugins.themes.bootstrap3.article.details##

Keywords

nasopharyngeal cancer, intensity modulated radiation therapy, volumetric modulated arc therapy, xerostomia

References
1. Chambers MS, Rosenthal DI, Weber RS, et al. Radiation-induced xerostomia. Head Neck 2007; 29(1):58-63.
2. Rubin P, Constine LS, Marks LB. ALERT Adverse Late Effects of Cancer Treatment: Volume 1: General Concepts and Specific Precepts, Volume 2: Normal Tissue Specific Sites and Systems, New York: Springer, 2014.
3. Rathod S, Gupta T, Ghosh-Laskar S, et al. Quality-of-life (QOL) outcomes in patients with head and neck squamous cell carcinoma (HNSCC) treated with intensity-modulated radiation therapy (IMRT) compared to three-dimensional conformal radiotherapy (3D-CRT): evidence from a prospective randomized study. Oral Oncol 2013; 49(6):634-642.
4. Nishimura Y, Komaki R. Intensity-Modulated Radiation Therapy, Clinical Evidence and Techniques, Tokio: Springer, 2015.
5. Jensen SB, Pedersen AM, Vissink A, et al. A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: prevalence, severity and impact on quality of life. Support Care Cancer 2010; 18(8):1039-1060.
6. Ozdemir S, Coban Y, Akin M, et al. Dosimetric evaluation of nasopharyngeal carcinomas irradiated with different IMRT techniques. J BUON 2014; 19(4):953-957.
7. Orlandi E, Giandini T, Iannacone E, et al. Radiotherapy for unresectable sinonasal cancers: dosimetric comparison of intensity modulated radiation therapy with coplanar and non-coplanar volumetric modulated arc therapy. Radiother Oncol 2014; 113(2):260-266.
8. Obinata K, Nakamura M, Carrozzo M, et al. Changes in parotid gland morphology and function in patients treated with intensity-modulated radiotherapy for nasopharyngeal and oropharyngeal tumors. Oral Radiol 2014; 30:135-141.
9. Wu Q, Chi Y, Chen PY, et al. Adaptive replanning strategies accounting for shrinkage in head and neck IMRT. Int J Radiat Oncol Biol Phys 2009; 75(3):924-932.
10. Wang ZH, Yan C, Zhang ZY, et al. Radiation-induced volume changes in parotid and submandibular glands in patients with head and neck cancer receiving postoperative radiotherapy: a longitudinal study. Laryngoscope 2009; 119(10):1966-1974.
11. Wang W, Yang H, Mi Y. Rules of parotid gland dose variations and shift during intensity modulated radiation therapy for nasopharyngeal carcinoma. Radiat Oncol 2015; 10:3.
12. Yao JJ, Chen FP, Zhou GQ, et al. A prospective study on radiation doses to organs at risk (OARs) during intensity-modulated radiotherapy for nasopharyngeal carcinoma patients. Oncotarget 2016; 7(16):21742-21752.
13. Little M, Schipper M, Feng FY, et al. Reducing xerostomia after chemo-IMRT for head-and-neck cancer: beyond sparing the parotid glands. Int J Radiat Oncol Biol Phys 2012; 83(3):1007-1014.
14. Moretto F, Rampino M, Munoz F, et al. Conventional 2D (2D-RT) and 3D conformal radiotherapy (3D-CRT) versus intensity-modulated radiotherapy (IMRT) for nasopharyngeal cancer treatment. Radiol Med 2014; 119(8):634-641.
How to Cite
Mireștean, C., Buzea, C. G., Butuc, I., Zara, A., & Iancu, D. T. (2017). Comparative evaluation of the doses received by the parotid glands as predictors of xerostomia be 3D-CRT, IMRT and VMAT irradiation techniques in local advanced nasopharynx cancer. Archive of Clinical Cases, 4(3), Arch Clin Cases 2017; 4(3):146-153. https://doi.org/10.22551/2017.16.0403.10107
Section
Original studies

How to Cite

Mireștean, C., Buzea, C. G., Butuc, I., Zara, A., & Iancu, D. T. (2017). Comparative evaluation of the doses received by the parotid glands as predictors of xerostomia be 3D-CRT, IMRT and VMAT irradiation techniques in local advanced nasopharynx cancer. Archive of Clinical Cases, 4(3), Arch Clin Cases 2017; 4(3):146-153. https://doi.org/10.22551/2017.16.0403.10107